The teams that are filing first are filing with REGARA™.
We work with regulatory leaders at medical device, pharma, and diagnostics companies — from early-stage breakthroughs to global multinationals. Names and case studies coming soon.
We're protective of our customers' time and IP.
Regulatory work is, by nature, confidential. We're working with our earliest customers to publish results in a form that respects both — typically anonymized for the first year of a program. The first case studies will be published here in Q3 2026.
Across the medical product landscape.
Cardiovascular, orthopedics, surgical robotics, neurostimulation, AI-enabled diagnostic imaging.
Oncology, rare disease, advanced therapies, biosimilars — small to mid-cap sponsors filing globally.
Molecular diagnostics, companion diagnostics, multi-cancer early detection, NGS-based assays.
"Customer testimonials will live here. Replace with attributed quotes when references are available."
Metrics will publish with first wave of case studies, Q3 2026.
Want to talk to someone using it?
Tell us a bit about your program and we'll connect you to a customer whose pathway looks like yours — under mutual NDA.